KCM
LLY icon

Kaye Capital Management’s Eli Lilly LLY Stock Holding History

Kaye Capital Management’s Portfolio LLY Stock Details LLY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		$546K Buy
701
+5
+0.7% +$3.88K 0.21% 31
2025
Q1 		$575K Buy
696
+1
+0.1% +$832 0.23% 31
2024
Q4 		$536K Buy
695
+1
+0.1% +$828 0.24% 26
2024
Q3 		$615K Buy
694
+1
+0.1% +$899 0.25% 27
2024
Q2 		$627K Buy
693
+3
+0.4% +$2.4K 0.26% 26
2024
Q1 		$536K Buy
690
+2
+0.3% +$1.42K 0.23% 25
2023
Q4 		$434K Buy
688
+1
+0.1% +$584 0.19% 27
2023
Q3 		$369K Buy
687
+1
+0.1% +$515 0.17% 28
2023
Q2 		$322K Sell
686
-52
-7% -$21.8K 0.16% 26
2023
Q1 		$253K Buy
738
+3
+0.4% +$1.01K 0.13% 29
2022
Q4 		$269K Buy
+735
New +$261K 0.14% 26

Other funds holding LLY

Lilly Endowment
Lilly Endowment Indiananapolis, Indiana $108B AUM 53.87% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Kaye Capital Management's LLY Position: Q2 2025 in Review

Kaye Capital Management increased its Eli Lilly (LLY) stake by 0.72% in Q2 2025, buying an estimated $3.88K and bringing the position to 701 shares worth $546K. The position accounts for 0.21% of the portfolio, ranked #31.

Kaye Capital Management first reported a position in LLY in Q4 2022 and has held it in 11 quarters since. The position peaked at $627K in Q2 2024. 3,906 funds tracked by Wall St. Rank hold LLY as of Q2 2025.

  • Kaye Capital Management held 701 shares of Eli Lilly worth $546K as of Q2 2025.
  • Kaye Capital Management bought 5 Eli Lilly shares in Q2 2025, an estimated $3.88K.
  • Eli Lilly made up 0.21% of Kaye Capital Management's portfolio in Q2 2025, its #31 holding.
  • Kaye Capital Management first reported a position in Eli Lilly in Q4 2022 and has held it in 11 quarters since.
  • Kaye Capital Management's Eli Lilly position peaked at $627K in Q2 2024.
  • 3,906 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2025.

Based on Kaye Capital Management's 13F filing for Q2 2025, filed 12 Aug 2025.